

## REMARKS/ARGUMENTS

Claims 7-29, 33-38, 43, 55, 56, 59-63, 67, 70-87, 92-95 and 117-129 are currently under consideration. Applicants note with appreciation that claims 67 and 126-129 have been allowed. As requested by the Examiner in a telephonic interview on October 21, 2004, Applicants hereby cancel the previously withdrawn claims 39-42, 44-54, 57-58, 64-65 and 96-116. For the remaining claims under consideration, Applicants respectfully request reconsideration in view of the following remarks and claim amendments. Issues raised in the Office Action will be addressed below in the order they appear in the Action.

1. Claim 38 is rejected under 35 U.S.C. 112, first paragraph, as containing subject matter which was not described in the specification in such a way as to enable one skilled in the art to which it pertains, or with which it is most nearly connected, to make and/or use the invention. Applicants traverse this rejection. Claim 38 is drawn to the compositions of claims 22-29, wherein the antigen-binding domain is cross-linked to a polymer. Applicants submit that, contrary to the statement in the Action, the specification provides examples of how to achieve this without destroying the binding activity of the antigen binding domain. For example, in Example 8 of the specification, two anti-HLA-DR antibody fragments, each of which has its V<sub>H</sub> chain fused to a FLAG epitope, were cross-linked to each other via an anti-FLAG antibody. This was accomplished by incubating the anti-HLA-DR antibody fragments together with anti-FLAG M2 monoclonal antibody (see page 58 of the specification). In making the rejection, the Examiner simply repeated the reasoning from the last Office Action without specifically addressing Applicants' argument raised in the response dated January 26, 2004. Nevertheless, solely to expedite prosecution of the remaining claims, Applicants hereby cancel claim 38, and reserve the right to pursue claims of similar scope in a future application.

2. Claims 13-16 are rejected under 35 U.S.C. 112, first paragraph, as containing subject matter which was not described in the specification in such a way as to enable one skilled in the art to which it pertains, or with which it is most nearly connected, to make and/or use the invention. Specifically, the Examiner questioned whether cell lines KARPAS-422, GRANTA-519, LG2 and PRIESS are publicly available (page 3 of the Office Action). Applicants submit

that cell lines KARPAS-422, GRANTA-519, and PRIESS are available through public depositories such as ECACC (European Collection of Cell Cultures) and DSMZ (Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH, *i.e.*, German Collection of Microorganisms and Cell Cultures, Ltd). In the response dated January 25, 2004, Applicants already amended claims 13-16 to include their corresponding catalogue numbers. Any one who wishes to use these cell lines can readily obtain them from the public depositories using the catalogue numbers provided. As further evidence of the public availability of cell lines KARPAS-422, GRANTA-519, and PRIESS, Applicants hereby attach printouts from ECACC and DSMZ web catalogues listing these cell lines. The issue regarding LG2, the fourth cell line, is rendered moot by Applicants' amendments of claims 13-16 to delete the recitation of LG2 cell line. Applicants note with appreciation that, in the telephonic interview with the Examiner on October 21, 2004, the Examiner agreed that the evidence of the public availability of the cell lines would be sufficient to overcome the rejection. Accordingly, withdrawal of the rejections are respectfully requested.

3. Claims 7-19, 22-29, 33-38, 43, 55, 56, 59-63, 73-77, 80-87, 92-95, 117-118, 122, 124 and 125 are rejected under 35 U.S.C. 112, first paragraph, as failing to comply with written description requirement and enablement requirement. Applicants traverse the rejection and submit that these claims satisfy written description and enablement requirement. Nevertheless, solely to expedite prosecution, Applicants hereby amend claims 17, 18, 20, 22-24, 26, 28, 71, 73-78, 81, 82, 84, 86, 92, 120, 121 and cancel claims 70, 80 and 119 to obviate the rejections.

In addition, Applicants amend claims 22-24, 26, 28 and 126 to delete the recitation of "in a manner where neither cytotoxic entities nor immunological mechanisms are needed for said killing." In a telephonic interview with the Examiner conducted on October 24, 2004, Applicants proposed these amendments and the Examiner indicated that the amendments would be acceptable and would be sufficient to overcome the rejection. Accordingly, withdrawal of the rejections are respectfully requested.

4. Applicants note with appreciation that the Examiner deemed claims 20, 21, 70-72, 78, 79, 119-121 and 123 allowable if rewritten to include all of the limitations of the base claims and all intervening claims. Applicants submit that the base claims, as amended, are now allowable.


**CONCLUSION**

In view of the foregoing amendments and remarks, Applicants submit that the pending claims are in condition for allowance. Early and favorable reconsideration is respectfully solicited. The Examiner is invited to contact the undersigned at 617-951-7000. A petition for an one-month extension of time, with authorization to charge the required fee to Deposit Account No. 18-1945, Order No. GPCG-P01-003, is being filed concurrently. If a further extension is required, Applicants' attorney respectfully requests that such extension be granted and any fee required be charged to Deposit Account No. 18-1945, Order No. GPCG-P01-003.

Respectfully Submitted,

Date: November 12, 2004

***Customer No: 28120***  
Docketing Specialist  
Ropes & Gray  
One International Place  
Boston, MA 02110  
Phone: 617-951-7000  
Fax: 617-951-7050



---

Weishi Li  
Reg. No. 53, 217


[BACK](#)

## HLA Defined

ECACC No. 86052111

Cell Line Name PRIESS

### HLA General Parameters

IHW Number	9301
Sex	F
Ethnic Origin	Danish
Consanguineous	No
Homozygous	Yes
WS Region	DEN
Lab Code	SVE
DNA Available from Stock	No
Keywords	Danish 9301

### Serological Profile (Class 1 and Class 2 Antigens)

HLA A	2
HLA C	3
HLA B	62
bw4/bw6	6
HLA DP	3 4
HLA DQ	8
HLA DR	4
HLA DR53	53
HLA Dw	4
HLA DPA1*	103
HLA DPB1*	0301 0401
HLA DQA1*	3
HLA DRB4*	101

The ECACC collections represent deposits of cell cultures from world-wide sources. While every effort is made to ensure details distributed by ECACC are accurate, ECACC cannot be held responsible for any inaccuracies in the data supplied. References where quoted are mainly attributed to the establishment of the cell culture and not for any specific property of the cell line, therefore further references should be obtained regarding cell culture characteristics. Passage numbers where given act only as a guide and ECACC does not guarantee the passage number stated will be the passage number received by the customer.

### Delivery State

Price Code - A

- ☒ Frozen - ?150.00  
☐ Growing - ?200.00  
☐ DNA - Please call +44 (0)1980 612512 for Prices.

### Quantity Required

### Prices & Ordering


Click the 'UPDATE' button to refresh the price for the quantity of packs required.  
Click the Basket button to add this product to your order.


[BACK](#)
[UPDATE](#)

Net Total

?150.00





GRANTA-519

DSMZ

© by DSMZ-Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH

Cell line GRANTA-519  
 Cell type human B cell lymphoma  
 DSMZ No ACC 342  
 Origin established from the peripheral blood taken in 1991 at relapse of grade B-NHL (leukemic transformation of mantle cell lymphoma, stage IV) diagnosed in a 58-year-old Caucasian woman with previous history of cervical carcinoma  
 Depositor Dr. D. Jayadel, Institute of Cancer Research, Sutton, Surrey, UK  
 Reference Rudolph et al., Cancer Genet Cytogenet, 153: 2004, 144-150, PubMed  
 Reference Jadayel et al., Leukemia, 11: 1997, 64, PubMed ID 9001420  
 Reference review: Drexler et al., Leuk Res, 26: 2002, 781, PubMed ID 12127

## DSMZ Cell Culture Data

Morphology spheroid cells growing in suspension, singly or in clumps  
 Medium 90% Dulbecco's MEM (4.5 g/L glucose) + 10% FBS + 2 mM L-glutamine  
 Subculture maintain at  $0.5-1.5 \times 10^6$  cells/ml; split ratio of 1:4 every 3 days; out at ca.  $1.0 \times 10^6$  cells/ml  
 Incubation at 37 °C with 5-10% CO<sub>2</sub>  
 Doubling time doubling time of about 49 hours  
 Harvest maximum density of about  $2.6 \times 10^6$  cells/ml  
 Storage frozen with 70% medium, 20% FBS, 10% DMSO at about  $5-7 \times 10^6$  cells/ampoule

## DSMZ Scientific Data

Mycoplasma contamination was eliminated with BM-Cyclin (tiamulin & minocycline); negative in DAPI, microbiological culture, RNA hybridization, PCR  
 Immunology CD3-, CD10-, CD13(+), CD19+, CD20+, CD30(+), CD34-, CD37+, CD79a+, cyCD79a+, CD80+, CD138+, HLA-DR+, sm/cyIgG-, sm/cyIgM+, sm/cykappa-, sm/cylambda+  
 Fingerprint multiplex PCR of minisatellite markers revealed a unique DNA profile  
 Species confirmed as human with IEF of AST, LDH, MDH  
 Cytogenetics human hypodiploid karyotype with 8% polyploidy; 44(39-44)<2n>XX,-17,-18,+mar,add(1)(p22),del(3)(p14p23),i(8p),i(8q),add(9)t(11;14)(q13;q32),add(13)(p12),add(18)(q21); sideline with two of der(14) and der(9); carries t(11;14) and rearrangement at 9p2 associated with cyclin D1 activation and deletion of p15/p16; main published karyotype  
 Viruses ELISA: reverse transcriptase negative; PCR: EBV+, HBV-, HCV-, HHV-8-, HIV-, HTLV-I/II-

DSMZ

Index

Prices

Dept. of Human and Animal Cell Lines



KARPAS-422

DSMZ

© by DSMZ-Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH

Cell line KARPAS-422  
 Cell type human B cell lymphoma  
 DSMZ No ACC 32  
 Origin established from the pleural effusion of a 73-year-old woman with non-Hodgkin lymphoma (intraabdominal, diffuse large cell lymphoma refractory, terminal) in 1987; carries t(14;18) IGH-BCL2 fusion (breakpoint in major breakpoint region, MBR)  
 Depositor Dr. A. Karpas, University of Cambridge, Cambridge, UK  
 Reference Dyer et al., Blood, 75: 1990, 709, PubMed ID 2297573

## DSMZ Cell Culture Data

Morphology round to polygonal cells, growing singly or in small clusters in  
 Medium 80-90% RPMI 1640 + 10-20% FBS  
 Subculture cells are difficult to culture! maintain at  $0.5-1.0 \times 10^6$  cells/ml every 3-4 days; seed out with 20% FBS at about  $1 \times 10^6$  cells/ml, possibly no cell growth during first week (we suggest to use fresh culture plates); upon thawing viability drops to about 50%  
 Incubation at 37 °C with 5% CO<sub>2</sub>  
 Doubling time doubling time of ca. 60-90 hours  
 Harvest maximal density at about  $2 \times 10^6$  cells/ml  
 Storage frozen with 70% medium, 20% FBS, 10% DMSO at about  $3-5 \times 10^6$  cells/ampoule

## DSMZ Scientific Data

Mycoplasma contamination was eliminated with BM-Cyclin (tiamulin & minocycline) then negative in DAPI, microbiological culture, RNA hybridization assays  
 Immunology CD3-, CD10+, CD13-, CD19+, CD20+, CD34-, CD37+, CD79a+, CD80-, CD138+, HLA-DR+, cyIgM-, cyIgG+, cyIgkappa+, cyIglambda-  
 Fingerprint multiplex PCR of minisatellite markers revealed a unique DNA profile  
 Species confirmed as human with IEF of AST, NP, PEP B  
 Cytogenetics human hyperdiploid karyotype with 10% polyploidy; 47(44-48)<2n>X+14, t(2;10)(p23;q22), t(4;11)(q21;q24), t(4;16)(q21;p13), der(14)t(14;18)(q32;q21)x2  
 Viruses ELISA: reverse transcriptase negative; PCR: EBV-, HBV-, HCV-, HHV-, HTLV-I/II-

DSMZ

Index

Prices

Dept. of Human and Animal Cell Lines